Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 22 studies | 42% ± 14% | |
astrocyte | 19 studies | 52% ± 21% | |
oligodendrocyte precursor cell | 14 studies | 48% ± 15% | |
microglial cell | 14 studies | 47% ± 15% | |
glutamatergic neuron | 13 studies | 70% ± 22% | |
oligodendrocyte | 13 studies | 38% ± 16% | |
macrophage | 12 studies | 37% ± 16% | |
GABAergic neuron | 11 studies | 65% ± 22% | |
fibroblast | 11 studies | 38% ± 11% | |
smooth muscle cell | 10 studies | 33% ± 12% | |
pericyte | 9 studies | 34% ± 13% | |
adipocyte | 9 studies | 52% ± 11% | |
epithelial cell | 8 studies | 36% ± 20% | |
mast cell | 8 studies | 33% ± 12% | |
neuron | 7 studies | 52% ± 21% | |
endothelial cell of lymphatic vessel | 7 studies | 35% ± 9% | |
interneuron | 6 studies | 69% ± 22% | |
retinal ganglion cell | 6 studies | 60% ± 29% | |
retinal cone cell | 6 studies | 66% ± 25% | |
B cell | 6 studies | 34% ± 11% | |
T cell | 6 studies | 35% ± 10% | |
amacrine cell | 5 studies | 54% ± 24% | |
cardiac muscle cell | 5 studies | 63% ± 15% | |
dendritic cell | 5 studies | 28% ± 7% | |
mesothelial cell | 5 studies | 36% ± 15% | |
retinal rod cell | 5 studies | 58% ± 22% | |
myeloid cell | 5 studies | 33% ± 6% | |
monocyte | 5 studies | 36% ± 10% | |
basal cell | 5 studies | 45% ± 20% | |
type I pneumocyte | 5 studies | 43% ± 8% | |
type II pneumocyte | 5 studies | 42% ± 7% | |
granule cell | 4 studies | 57% ± 12% | |
retinal bipolar neuron | 4 studies | 39% ± 22% | |
Mueller cell | 4 studies | 40% ± 16% | |
retina horizontal cell | 4 studies | 64% ± 21% | |
ciliated cell | 4 studies | 32% ± 12% | |
club cell | 4 studies | 42% ± 10% | |
natural killer cell | 4 studies | 34% ± 9% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 48% ± 8% | |
GABAergic interneuron | 3 studies | 77% ± 5% | |
progenitor cell | 3 studies | 30% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 32% ± 4% | |
CD8-positive, alpha-beta T cell | 3 studies | 30% ± 6% | |
plasma cell | 3 studies | 34% ± 8% | |
vein endothelial cell | 3 studies | 31% ± 14% | |
GABAergic amacrine cell | 3 studies | 68% ± 16% | |
OFF-bipolar cell | 3 studies | 58% ± 13% | |
ON-bipolar cell | 3 studies | 62% ± 14% | |
glycinergic amacrine cell | 3 studies | 56% ± 12% | |
endothelial cell of vascular tree | 3 studies | 37% ± 15% | |
hepatocyte | 3 studies | 67% ± 18% | |
retinal pigment epithelial cell | 3 studies | 51% ± 25% | |
ependymal cell | 3 studies | 54% ± 19% | |
alveolar macrophage | 3 studies | 43% ± 8% | |
respiratory goblet cell | 3 studies | 48% ± 17% | |
lymphocyte | 3 studies | 44% ± 12% | |
goblet cell | 3 studies | 39% ± 27% | |
mucus secreting cell | 3 studies | 42% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 2672.81 | 2640 / 2642 | 100% | 24.02 | 704 / 705 |
thymus | 100% | 1800.29 | 652 / 653 | 100% | 19.31 | 603 / 605 |
adrenal gland | 100% | 1903.75 | 258 / 258 | 99% | 17.68 | 228 / 230 |
kidney | 100% | 1239.58 | 89 / 89 | 99% | 15.99 | 891 / 901 |
breast | 100% | 1541.56 | 459 / 459 | 99% | 14.96 | 1105 / 1118 |
prostate | 100% | 1227.13 | 244 / 245 | 99% | 13.49 | 498 / 502 |
stomach | 100% | 953.62 | 359 / 359 | 99% | 10.43 | 282 / 286 |
esophagus | 100% | 1279.67 | 1445 / 1445 | 98% | 10.66 | 180 / 183 |
intestine | 100% | 1278.94 | 966 / 966 | 97% | 9.86 | 513 / 527 |
lung | 99% | 1046.89 | 571 / 578 | 98% | 9.17 | 1127 / 1155 |
uterus | 100% | 1338.04 | 170 / 170 | 96% | 8.61 | 441 / 459 |
bladder | 100% | 1491.19 | 21 / 21 | 96% | 8.60 | 483 / 504 |
ovary | 99% | 1014.74 | 179 / 180 | 95% | 8.95 | 410 / 430 |
pancreas | 96% | 647.71 | 314 / 328 | 99% | 10.58 | 176 / 178 |
liver | 98% | 710.54 | 221 / 226 | 93% | 7.46 | 379 / 406 |
skin | 100% | 1411.40 | 1807 / 1809 | 89% | 9.91 | 421 / 472 |
adipose | 100% | 1593.42 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2172.99 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 3474.98 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 987.20 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.61 | 1 / 1 |
lymph node | 0% | 0 | 0 / 0 | 97% | 8.04 | 28 / 29 |
heart | 96% | 1803.53 | 826 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 9.64 | 43 / 45 |
eye | 0% | 0 | 0 / 0 | 59% | 4.00 | 47 / 80 |
peripheral blood | 54% | 363.12 | 500 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008589 | Biological process | regulation of smoothened signaling pathway |
GO_0043153 | Biological process | entrainment of circadian clock by photoperiod |
GO_0014033 | Biological process | neural crest cell differentiation |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0006515 | Biological process | protein quality control for misfolded or incompletely synthesized proteins |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0007399 | Biological process | nervous system development |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXL17 |
Protein name | F-box/LRR-repeat protein 17 (F-box and leucine-rich repeat protein 17) (F-box only protein 13) F-box and leucine rich repeat protein 17 F-box and leucine-rich repeat protein 17 |
Synonyms | FBXO13 FBX13 FBL17 |
Description | FUNCTION: Substrate-recognition component of the SCF(FBXL17) E3 ubiquitin ligase complex, a key component of a quality control pathway required to ensure functional dimerization of BTB domain-containing proteins (dimerization quality control, DQC) . FBXL17 specifically recognizes and binds a conserved degron of non-consecutive residues present at the interface of BTB dimers of aberrant composition: aberrant BTB dimer are then ubiquitinated by the SCF(FBXL17) complex and degraded by the proteasome . The ability of the SCF(FBXL17) complex to eliminate compromised BTB dimers is required for the differentiation and survival of neural crest and neuronal cells (By similarity). The SCF(FBXL17) complex mediates ubiquitination and degradation of BACH1 . The SCF(FBXL17) complex is also involved in the regulation of the hedgehog/smoothened (Hh) signaling pathway by mediating the ubiquitination and degradation of SUFU, allowing the release of GLI1 from SUFU for proper Hh signal transduction . The SCF(FBXL17) complex mediates ubiquitination and degradation of PRMT1 (By similarity). . |
Accessions | Q9UF56 ENST00000542267.7 [Q9UF56-1] ENST00000496714.2 H7C835 A0A6E1XD66 |